Restoring dependence

Netris Pharma S.A.S. is aiming to boost rates and durations of responses to immunotherapies by targeting a population of slow-growing cells these therapies leave behind. The biotech’s mAbs restore the pro-apoptotic function of dependence receptors, and could be useful in combinations to root out slowly proliferating cancer stem cells.

By February, the company expects to have data from a Phase I trial of NP137 in solid tumors that will help determine the dose to take forward in combination studies...